Literature DB >> 15735049

Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.

Barbara Jarzab1, Malgorzata Wiench, Krzysztof Fujarewicz, Krzysztof Simek, Michal Jarzab, Malgorzata Oczko-Wojciechowska, Jan Wloch, Agnieszka Czarniecka, Ewa Chmielik, Dariusz Lange, Agnieszka Pawlaczek, Sylwia Szpak, Elzbieta Gubala, Andrzej Swierniak.   

Abstract

The study looked for an optimal set of genes differentiating between papillary thyroid cancer (PTC) and normal thyroid tissue and assessed the sources of variability in gene expression profiles. The analysis was done by oligonucleotide microarrays (GeneChip HG-U133A) in 50 tissue samples taken intraoperatively from 33 patients (23 PTC patients and 10 patients with other thyroid disease). In the initial group of 16 PTC and 16 normal samples, we assessed the sources of variability in the gene expression profile by singular value decomposition which specified three major patterns of variability. The first and the most distinct mode grouped transcripts differentiating between tumor and normal tissues. Two consecutive modes contained a large proportion of immunity-related genes. To generate a multigene classifier for tumor-normal difference, we used support vector machines-based technique (recursive feature replacement). It included the following 19 genes: DPP4, GJB3, ST14, SERPINA1, LRP4, MET, EVA1, SPUVE, LGALS3, HBB, MKRN2, MRC2, IGSF1, KIAA0830, RXRG, P4HA2, CDH3, IL13RA1, and MTMR4, and correctly discriminated 17 of 18 additional PTC/normal thyroid samples and all 16 samples published in a previous microarray study. Selected novel genes (LRP4, EVA1, TMPRSS4, QPCT, and SLC34A2) were confirmed by Q-PCR. Our results prove that the gene expression signal of PTC is easily detectable even when cancer cells do not prevail over tumor stroma. We indicate and separate the confounding variability related to the immune response. Finally, we propose a potent molecular classifier able to discriminate between PTC and nonmalignant thyroid in more than 90% of investigated samples.

Entities:  

Mesh:

Year:  2005        PMID: 15735049     DOI: 10.1158/0008-5472.CAN-04-3078

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Three-gene molecular diagnostic model for thyroid cancer.

Authors:  Nijaguna B Prasad; Jeanne Kowalski; Hua-Ling Tsai; Kristin Talbot; Helina Somervell; Guennadi Kouniavsky; Yongchun Wang; Alan P B Dackiw; William H Westra; Douglas P Clark; Steven K Libutti; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2012-01-26       Impact factor: 6.568

2.  Identification of novel retinal target genes of thyroid hormone in the human WERI cells by expression microarray analysis.

Authors:  Yan Liu; Li Fu; Ding-Geng Chen; Samir S Deeb
Journal:  Vision Res       Date:  2007-07-25       Impact factor: 1.886

3.  Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.

Authors:  Beatrice W T Yin; Ramziya Kiyamova; Ramon Chua; Otavia L Caballero; Ivan Gout; Vitalina Gryshkova; Nimesh Bhaskaran; Serhiy Souchelnytskyi; Ulf Hellman; Valeriy Filonenko; Achim A Jungbluth; Kunle Odunsi; Kenneth O Lloyd; Lloyd J Old; Gerd Ritter
Journal:  Cancer Immun       Date:  2008-02-06

4.  Upregulation of the Na⁺-coupled phosphate cotransporters NaPi-IIa and NaPi-IIb by B-RAF.

Authors:  Tatsiana Pakladok; Zohreh Hosseinzadeh; Aleksandra Lebedeva; Ioana Alesutan; Florian Lang
Journal:  J Membr Biol       Date:  2013-11-21       Impact factor: 1.843

5.  ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study.

Authors:  Qiu-li Li; Fu-jin Chen; Renchun Lai; Zhu-ming Guo; Rongzhen Luo; An-kui Yang
Journal:  Med Oncol       Date:  2011-07-08       Impact factor: 3.064

6.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

7.  Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

Authors:  Debora Degl'Innocenti; Chiara Alberti; Giancarlo Castellano; Angela Greco; Claudia Miranda; Marco A Pierotti; Ettore Seregni; Maria Grazia Borrello; Silvana Canevari; Antonella Tomassetti
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

8.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

9.  Myotubularin-related protein 4 (MTMR4) attenuates BMP/Dpp signaling by dephosphorylation of Smad proteins.

Authors:  Junjing Yu; Xiaomeng He; Ye-Guang Chen; Yan Hao; Shuo Yang; Lei Wang; Lei Pan; Hong Tang
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

10.  Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.

Authors:  Jean-Fred Fontaine; Delphine Mirebeau-Prunier; Mahatsangy Raharijaona; Brigitte Franc; Stephane Triau; Patrice Rodien; Olivier Goëau-Brissonniére; Lucie Karayan-Tapon; Marielle Mello; Rémi Houlgatte; Yves Malthiery; Frédérique Savagner
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.